TPG, a global alternative asset management firm, has entered into a binding agreement to acquire a 35% stake in SCHOTT ...

TPG acquires 35% stake in SCHOTT Poonawalla from Serum Institute of India; SCHOTT Pharma retains 50% while SII continues as ...

TPG is making the investment along with Danish firm Novo Holdings as a co-investor. SII, the world's largest vaccine maker, ...

Global alternative asset firm TPG has acquired a 35% stake in SCHOTT Poonawalla, a joint venture between SCHOTT Pharma and ...

Global investment firm TPG has signed a legally binding agreement to purchase a 35% ownership in SCHOTT Poonawalla, the joint venture between Serum Institute of India (SII) and Germany-based SCHOTT ...

TPG is acquiring a 35% stake in SCHOTT Poonawalla, a joint venture of SCHOTT Pharma and Serum Institute of India. The deal is ...

TPG has entered into a binding agreement to acquire 35% stake in Schott Poonawalla from Serum Institute of India (SII), said ...

TPG Growth, TPG’s middle market and growth equity platform, is funding the investment, along with Novo Holdings as a ...

TPG will acquire a 35% stake in SCHOTT Poonawalla from the Serum Institute of India. This joint venture with SCHOTT Pharma is ...

SCHOTT Poonawalla is a joint venture of SCHOTT Pharma and SII, part of the Cyrus Poonawalla Group and a global leader in vaccine manufacturing, dedicated to providing affordable vaccines worldwide.

Global alternative asset management firm TPG has entered into a binding agreement to acquire a 35% stake in Schott Poonawalla ...